SCHEMBL5889659

SCHEMBL5889659

CC(C)CCn1cc(NC(=O)c2ccc(C(=O)Nc3cc(C(=O)NCCC(=N)NC(C)C)n(CCC(C)C)c3)cc2)cc1C(=O)NCCC(=N)NC(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRAS P01112 10/20 0.41
ESR1 P03372 10/20 0.41
ESR2 Q92731 10/20 0.41
TOP1 P11387 2/20 0.41
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
HIF1A Q16665 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NAMPT P43490 3/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889825 0.92 HRAS (0.43) HRASESR1ESR2TOP1KDM4E
SCHEMBL5889526 0.89 HRAS (0.53) HRASESR1ESR2TOP1KDM4E
SCHEMBL6495181 0.86 HRAS (0.51) HRASESR1ESR2TOP1KDM4E
SCHEMBL5889546 0.85 HRAS (0.42) HRASESR1ESR2TOP1KDM4E
SCHEMBL6489771 0.85 HRAS (0.47) HRASESR1ESR2TOP1KDM4E
SCHEMBL6486747 0.84 HRAS (0.46) HRASESR1ESR2TOP1KDM4E
SCHEMBL5889536 0.84 TERT (0.42) MEN1KMT2ANAMPTRAB9ASMN1; SMN2
SCHEMBL5889631 0.83 HRAS (0.40) HRASESR1ESR2TOP1KDM4E
SCHEMBL5889513 0.82 NAMPT (0.38) HRASESR1ESR2TOP1KDM4E
SCHEMBL5889791 0.82 MEN1 (0.38) HRASESR1ESR2TOP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064218-B2 Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2006-06-20 US disclosed
US-6956040-B2 Oxazolidinone piperazinyl derivatives as potential antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2005-10-18 US disclosed
US-6906103-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-06-14 US disclosed
US-6849713-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-02-01 US disclosed
US-20040254162-A1 Oxazolidinone derivatives as antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2004-12-16 US disclosed
US-6734307-B2 USE AGAINST MULTIPLY RESISTANT GRAM POSITIVE PATHOGENS; HAVE A DIAZINE MOIETY ATTACHED TO THE PHENYLOXAZOLIDINONE WHICH IS FURTHER SUBSTITUTED BY HETEROCYCLIC, ARYL, SUBSTITUTED ARYL, HETEROAROAMATIC RING RANBAXY LABORATORIES LIMITED (IN) 2004-05-11 US disclosed
EP-1409465-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2004-04-21 EP disclosed
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GLAXOSMITHKLINE LLC 2003-11-13 US disclosed
WO-2003057212-A1 POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-07-17 WO disclosed
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials MEHTA ANITA (IN) 2003-06-26 US disclosed
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity SMITHKLINE BEECHAM CORPORATION 2003-06-26 US disclosed
EP-1303511-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2003-04-23 EP disclosed
EP-1294713-A2 COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-03-26 EP disclosed
WO-2002000650-A9 NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECH INC (US) 2003-03-06 WO disclosed
WO-2003007870-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2003-01-30 WO disclosed
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease RANBAXY LABORATORIES LIMITED (IN) 2002-08-01 US disclosed
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. 2002-03-28 US disclosed
WO-2002006278-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2002-01-24 WO disclosed
WO-2002000650-A2 NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials OXA1L, PDK4, SDHA HRAS 3646/4885ESR1 3213/4885ESR2 3755/4885
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 HRAS 402/4885ESR1 4097/4885ESR2 3377/4885
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease OXA1L, MLYCD, TBCD HRAS 3693/4885ESR1 1948/4885ESR2 2909/4885
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 HRAS 402/4885ESR1 4097/4885ESR2 3377/4885
US-20040254162-A1 Oxazolidinone derivatives as antimicrobials PPARD, PDK4, OXA1L HRAS 4066/4885ESR1 3329/4885ESR2 3420/4885
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity TYR, CYP51A1, ODC1 HRAS 1040/4885ESR1 4541/4885ESR2 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.